Journals / Turkish Journal of Pediatrics / 2020 / Cilt: 62 - Sayı: 5

Carbapenem and colistin resistance in children with Enterobacteriaceae infections

Pages
778–786
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recognizing the risk factors of carbapenem and colistin resistant Enterobacteriaceae infections is essential in order to conserve carbapenem and colistin since there are no new antibiotics to treat multidrug-resistant Enterobacteriaceae infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Carbapenem-resistant Enterobacteriaceae (CRE) are an emerging global public health threat.
📊
Key Findings & Data:We conducted a retrospective study in a single university hospital between the years 2013 and 2017 including 150 patients with Enterobacteriaceae infections.
💡
Conclusion & Impact:Recognizing the risk factors of carbapenem and colistin resistant Enterobacteriaceae infections is essential in order to conserve carbapenem and colistin since there are no new antibiotics to treat multidrug-resistant Enterobacteriaceae infections.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Background. Carbapenem-resistant Enterobacteriaceae (CRE) are an emerging global public health threat. As a reserve agent, colistin has been the drug of choice for the treatment of infections caused by CRE. The aim of this study was to determine the risk factors of carbapenem and colistin-resistant Enterobacteriaceae infections and to investigate the outcomes. Methods. We conducted a retrospective study in a single university hospital between the years 2013 and 2017 including 150 patients with Enterobacteriaceae infections. Results. Of 150 Enterobacteriaceae infections, 62 (41%) were carbapenem and 23 (15%) were colistin-resistant. Colistin resistance rates among Enterobacteriaceae species increased from 4% in 2014 to 25% in 2017. The in-hospital mortality of the patients with colistin-resistant and with carbapenem-resistant infections were 39% (9/23) and 45% (28/62), respectively. Prior exposure to polyantibiotic therapy for Gram negative bacteria was found as a predictor of CRE (OR = 6.4; 95% CI 3.07-13.6; p = 0.001) infections. The median length of hospital stay prior to positive culture (OR = 1.02; 95%CI, 1.0-1.04; p = 0.003) and history of surgery during the admission (OR = 2.46; 95% CI 1.2-5.1; p = 0.005) were found as the predictors of CRE infections. Underlying necrotizing enterocolitis and/or short-bowel syndrome (OR=6.38; 95%CI 1.16-35; p = 0.033) and mechanical ventilation prior to index culture were found as predictors of colistin resistance (OR = 9.4; 95% CI 2-40.4; p = 0.004).Conclusions. Recognizing the risk factors of carbapenem and colistin resistant Enterobacteriaceae infections is essential in order to conserve carbapenem and colistin since there are no new antibiotics to treat multidrug-resistant Enterobacteriaceae infections.

🔖

Cite This Article

YILDIZDAŞ, D., GÜNDEŞLİOĞLU, Ö. Ö., KOCABAŞ, E., HAYTOĞLU, Z., ALABAZ, D., HOROZ, Ö. Ö. (2022). Carbapenem and colistin resistance in children with Enterobacteriaceae infections. Turkish Journal of Pediatrics, Cilt: 62 - Sayı: 5, 778–786. https://ajindex.com/articles/613077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690. 2.Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology and management. Ann NY Acad Sci 2014; 1323: 22-42. 3.Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: E23-E30. 4.Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011; 66: 946-947. 5.Kontopidou F, Plachouras D, Papadomichelakis E, et al. Colonization and infection by colistin-resistant gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infec 2011; 17: E9-E11. 6.Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 60-67. 7.Ling ML, Tee YM, Tan SG, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control 2015; 4: 26. 8.Patel N, Harrington S, Dihmess A, et al. Clinical epidemiology of carbapenem-intermediate or-resistant Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 1600-1608. 9.Carbapenem-Resistant Enterobacteriaceae (CRE) Control and Prevention Toolkit 2012
  2. CER Toolkit Atlanta, GA: CDC, 2012. Available at: www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf [Updated 2015 November, cited 2017 May 15]. 10.European Society of Clinical Microbiology and Infectious Diseases. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints-bacteria(v7.1) [internet]. Switzerland: ESCMID, 2013. Available at: http:// www.eucast.org/clinical_breakpoints/ [Updated 2017 Dec 31, cited 2018 May 15]. 11.Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332. 12.Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-1106. 13.Husse